Business
Alembic Pharmaceuticals Posts Rs 202.7 Crore Quarterly Profit
Alembic Pharmaceuticals on Friday reported a strong rise in consolidated net profit for the fourth quarter of FY26, supported by revenue growth across business segments. The company also registered higher operational revenue compared to the same period last year.
Alembic Pharmaceuticals on Friday announced a 29 percent increase in consolidated net profit for the fourth quarter ended March 31, 2026.
According to a regulatory filing, the company posted a consolidated net profit of Rs 202.7 crore during the January-March quarter, compared to Rs 156.89 crore recorded in the corresponding period of the previous financial year.
The pharmaceutical company also reported growth in its consolidated revenue from operations. Revenue for the quarter stood at Rs 1,847.72 crore, up from Rs 1,769.64 crore in the same quarter of the previous fiscal year.
The company attributed the improved financial performance to revenue growth across multiple business segments, reflecting steady demand and operational expansion.
Alembic Pharmaceuticals is one of India’s prominent pharmaceutical firms and operates across domestic and international markets, manufacturing and marketing a wide range of formulations and active pharmaceutical ingredients.
The results come amid continued growth in the pharmaceutical and healthcare sector, driven by increasing demand for medicines, exports, and healthcare products in both Indian and global markets.
Industry analysts said the company’s improved profitability indicates stable operational performance and stronger business momentum during the quarter.